MA-BRIGHTCOVE
22.6.2020 05:32:09 CEST | Business Wire | Press release
Brightcove Inc. (NASDAQ: BCOV), the world’s leading video technology platform, announced today that BadaBusiness.com , an ed-tech platform founded by Dr. Vivek Bindra, has set two new Guinness World Records for the largest online business and sales lessons streamed, which were powered by Brightcove. The live webinars were joined by BadaBusiness.com’s customers, as well as attendees looking to ‘learn and earn at home’ by exploring the means of upskilling, training, and acquiring new business knowledge. These webinars are a part of Dr. Vivek Bindra’s ‘India Revival Mission,’ which derived from the impact of COVID-19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200621005050/en/
The first webinar, titled Largest Online Business Lesson , had a previous record of 12,091 unique attendees, and on April 24, 2020, the stream set a new world record of 18,693 attendees. The second world record was set by BadaBusiness.com on May 31, 2020, when it debuted its Largest Online Sales Lesson webinar with 95,087 attendees. BadaBusiness.com will be hosting the World's Largest Strategy Session on June 27, 2020, to mark International MSME Day .
Brightcove helps organizations in more than 70 countries meet business challenges through its robust, scalable, and intuitive video platform. Powering BadaBusiness.com’s online events is yet another example of how organizations are pushing the boundaries by inspiring, entertaining, and engaging their audiences through video. According to live analytics data captured by Brightcove’s platform, BadaBusiness.com achieved peak traffic of over 2.3 million total video views, over 1.3 million unique viewers, and 345,000 peak concurrent users during the live event on May 31st.
“Our mission is to provide extensive knowledge of practical business strategies and frameworks to enterprises across India so they can grow and strengthen their brand. With video, BadaBusiness.com is able to host online webinars to deliver those important business messages, while also experiencing better engagement with our audiences,” said Dr. Vivek Bindra, Founder of BadaBusiness.com. “Not only is it an accomplishment to simultaneously bring together nearly 100,000 attendees who share similar business goals, but we also broke two Guinness World Records, all thanks to Brightcove’s technology.”
“At Brightcove, we are always working with our customers to pursue unique and innovative use cases of video. BadaBusiness.com’s online events demonstrate how video can offer educational and informative content, while also being one of the best ways to bring people together virtually,” said Charles Chu, Chief Product Officer, Brightcove. “We’re ecstatic that BadaBusiness.com now holds two world records for the largest online streamed events while choosing Brightcove to power those experiences for their audiences.”
About BadaBusiness.com
A technology-enabled training company that provides affordable, available and accessible business training programs to MSME Business Owners, Entrepreneurs and Wantapreneurs in vernacular language, through a combination of online and offline delivery mechanisms. The objective is to empower individual entrepreneurs and small businesses to scale up, by providing them tools and problem-solving support ecosystem.
About Brightcove Inc. (NASDAQ: BCOV)
We are the people behind the world’s leading video technology platform. With our award-winning technology and services, we help organizations in more than 70 countries meet business challenges and create strategic opportunities by inspiring, entertaining, and engaging their audiences through video.
Since Brightcove was established in 2004, we have consistently pushed boundaries to create a platform for people who are serious about video: one that is robust, scalable, and intuitive. Benefiting from a global infrastructure, unrivalled customer support, an extensive partner ecosystem, and relentless investment in R&D, Brightcove video sets the standard for professional grade video management, distribution, and monetization. To learn more, visit www.brightcove.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200621005050/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom